Free Trial

Zynex Q2 2023 Earnings Report

Zynex logo
$8.18 -0.18 (-2.09%)
As of 02:25 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Zynex EPS Results

Actual EPS
$0.09
Consensus EPS
$0.04
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

Zynex Revenue Results

Actual Revenue
$44.95 million
Expected Revenue
$44.50 million
Beat/Miss
Beat by +$450.00 thousand
YoY Revenue Growth
N/A

Zynex Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Zynex Earnings Headlines

Zynex (ZYXI) Gets a Buy from RBC Capital
Ignore every stock…
Stocks have been on a tear in 2024… And there’s plenty of great opportunities out there. But one expert says you should forget about EVERY stock for a moment and focus on an even bigger opportunity. The current GOLD supercycle You see, stocks are a dime a dozen for the most part… And, fortunately, they go up more than they go down. But every few decades, precious metals have a systematic supercycle that tends to dwarf the potential of just about anything else. The last time things aligned like this on gold it surged 536%
See More Zynex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zynex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zynex and other key companies, straight to your email.

About Zynex

Zynex (NASDAQ:ZYXI), together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

View Zynex Profile

More Earnings Resources from MarketBeat